Drug Type Trispecific antibody |
Synonyms PF 07264660, PF07264660 |
Target |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), IL-33 inhibitors(Interleukin-33 inhibitors), IL-4 inhibitors(Interleukin-4 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Moderate Atopic Dermatitis | Phase 2 | US | 22 Aug 2023 | |
Moderate Atopic Dermatitis | Phase 2 | CN | 22 Aug 2023 | |
Moderate Atopic Dermatitis | Phase 2 | JP | 22 Aug 2023 | |
Moderate Atopic Dermatitis | Phase 2 | AU | 22 Aug 2023 | |
Moderate Atopic Dermatitis | Phase 2 | CA | 22 Aug 2023 | |
Severe Atopic Dermatitis | Phase 2 | US | 22 Aug 2023 | |
Severe Atopic Dermatitis | Phase 2 | CN | 22 Aug 2023 | |
Severe Atopic Dermatitis | Phase 2 | JP | 22 Aug 2023 | |
Severe Atopic Dermatitis | Phase 2 | AU | 22 Aug 2023 | |
Severe Atopic Dermatitis | Phase 2 | CA | 22 Aug 2023 |